Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity.

ABSTRACT:

Background and aims

Osteoarthritic patients treated with high doses of chondroitin sulfate (CS) have a lower incidence of coronary heart disease--but the mechanistic aspects of these beneficial effects of CS remain undefined. We examined how CS treatment affects the formation of atheroma via interaction with endothelial cells and monocytes.

Methods

We characterized arterial atheromatous plaques by multiphoton microscopy and serum pro-inflammatory cytokines by immunoenzymatic techniques in obese mice receiving CS (1 g/kg/day, i.p.) or vehicle for 6 days. Effects of CS on signaling pathways, cytokine secretion and macrophage migration were evaluated in cultures of human coronary endothelial cells and in a monocyte cell line stimulated with TNF-α by Western blot, immunoenzymati

SUBMITTER: Melgar-Lesmes P 

PROVIDER: S-EPMC4738029 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature